Hantz Financial Services Inc. acquired a new position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) during the fourth quarter, according to the company in its most recent filing ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Can-Fite BioPharma has secured a US patent for Namodenoson, its lead drug candidate, for use as an anti-obesity treatment.

HCR-188, a clinic-ready antibody, entering first-in-human clinical studies with top-line data anticipated in the second half ...

This study presents fundamental insights into overcoming resistance in hormone receptor-positive breast cancer by demonstrating that sustained CDK4/6 inhibitor treatment, either alone or in ...

The Namodenoson oral drug is well positioned in the field of anti-obesity agents due to its activity and favorable safety profile Ramat Gan, ...

Can-Fite BioPharma (CANF) announced that its lead drug candidate Namodenoson was granted a patent for its use as an anti-obesity drug by the US ...